MX2016006058A - Métodos para suprimir caquexia relacionada a cáncer. - Google Patents

Métodos para suprimir caquexia relacionada a cáncer.

Info

Publication number
MX2016006058A
MX2016006058A MX2016006058A MX2016006058A MX2016006058A MX 2016006058 A MX2016006058 A MX 2016006058A MX 2016006058 A MX2016006058 A MX 2016006058A MX 2016006058 A MX2016006058 A MX 2016006058A MX 2016006058 A MX2016006058 A MX 2016006058A
Authority
MX
Mexico
Prior art keywords
hdac inhibitors
suppressing cancer
related cachexia
mammal
hdac
Prior art date
Application number
MX2016006058A
Other languages
English (en)
Other versions
MX368293B (es
Inventor
Shih CHEN Ching-
BEKAII-SAAB Tanios
GUTTRIDGE Denis
MARCUCCI Guido
Kulp Samuel
Chou TSENG Yu-
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of MX2016006058A publication Critical patent/MX2016006058A/es
Publication of MX368293B publication Critical patent/MX368293B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan métodos para suprimir caquexia en un mamífero con cáncer que comprenden administrar inhibidores de HDAC. Los aspectos incluyen métodos para administrar un inhibidor de HDAC clase 1 y 2b en una cantidad efectiva para mantener sustancialmente el peso del mamífero en comparación a un mamífero que no recibe el inhibidor de HDAC clase 1 y 2b.
MX2016006058A 2013-11-20 2014-11-19 Métodos para suprimir caquexia relacionada a cáncer. MX368293B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361906738P 2013-11-20 2013-11-20
US14/547,771 US11219607B2 (en) 2013-11-20 2014-11-19 Methods for suppressing cancer-related cachexia
PCT/US2014/066435 WO2015077353A1 (en) 2013-11-20 2014-11-19 Hdac inhibitors for suppressing cancer-related cachexia

Publications (2)

Publication Number Publication Date
MX2016006058A true MX2016006058A (es) 2016-11-14
MX368293B MX368293B (es) 2019-09-27

Family

ID=52302303

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006058A MX368293B (es) 2013-11-20 2014-11-19 Métodos para suprimir caquexia relacionada a cáncer.

Country Status (8)

Country Link
US (1) US11219607B2 (es)
JP (1) JP6473152B2 (es)
KR (1) KR102091037B1 (es)
AU (1) AU2014353070B2 (es)
CA (2) CA3149871A1 (es)
MX (1) MX368293B (es)
RU (1) RU2692785C1 (es)
WO (1) WO2015077353A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6473152B2 (ja) 2013-11-20 2019-02-20 オハイオ・ステイト・イノベーション・ファウンデーション がん関連悪液質を抑制するためのｈｄａｃ阻害剤
EP3681493A4 (en) 2017-09-13 2021-06-09 The Ohio State Innovation Foundation METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER CACHEXIA
JPWO2021112196A1 (es) * 2019-12-05 2021-06-10

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275370A1 (en) * 2002-07-25 2006-12-07 Yih-Lin Chung Method and compositions for treatment of epithelial damage
CA2552279C (en) 2003-12-02 2014-07-15 The Ohio State University Research Foundation Zn2+-chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors
US20060229237A1 (en) * 2005-04-07 2006-10-12 Yih-Lin Chung Treatment of gastrointestinal distress
GB0612273D0 (en) * 2006-06-21 2006-08-02 Friedrich Miescher Inst For Bi Prevention of muscle atrophy
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
MX2014006409A (es) 2011-11-28 2014-07-30 Novartis Ag Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
EP2727465A1 (en) 2012-10-31 2014-05-07 Universitätsklinikum Freiburg Animal model for type 2 diabetes and obesity
JP6473152B2 (ja) 2013-11-20 2019-02-20 オハイオ・ステイト・イノベーション・ファウンデーション がん関連悪液質を抑制するためのｈｄａｃ阻害剤

Also Published As

Publication number Publication date
US11219607B2 (en) 2022-01-11
RU2692785C1 (ru) 2019-06-27
MX368293B (es) 2019-09-27
JP6473152B2 (ja) 2019-02-20
AU2014353070B2 (en) 2020-04-30
CA2930606C (en) 2022-05-10
JP2016537356A (ja) 2016-12-01
KR20160107161A (ko) 2016-09-13
RU2016118228A (ru) 2017-12-25
WO2015077353A1 (en) 2015-05-28
US20150150832A1 (en) 2015-06-04
CA2930606A1 (en) 2015-05-28
KR102091037B1 (ko) 2020-03-19
AU2014353070A1 (en) 2016-06-02
CA3149871A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
PH12019501197A1 (en) Therapeutically active compounds and their methods of use
ZA202208792B (en) Methods of treating and preventing graft versus host disease
MX2022007472A (es) Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario.
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
IL273090B (en) Methods and preparations for the treatment of cancer
MX2015006478A (es) Inhibidores de glutaminasa y metodos de empleo.
BR112015011830A2 (pt) compostos e seus métodos de utilização
IN2014MN02655A (es)
AU356290S (en) Jacket for portable speaker
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
AU356287S (en) Jacket for portable speaker
MX368293B (es) Métodos para suprimir caquexia relacionada a cáncer.
HK1251477A1 (zh) 包含氨基硫羥酸酯化合物或其藥學上可接受的鹽、與能夠增加受試者的癌細胞中h2o2水平的化合物的組合
LT3024825T (lt) Imidazolo karboksamidai ir jų panaudojimas kaip faah inhibitorių
MX2015014063A (es) Composicion anti tumoral que comprende un inhibidor selectivo pi3kbeta y un inhibidor selectivo pi3kalfa.
EA201491695A1 (ru) Лечение рака ингибиторами tor-киназы

Legal Events

Date Code Title Description
FG Grant or registration